JTJohn Tapsall

John Tapsall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Tapsall has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Sanghamitra Ray

    Neisseria Reference Laboratory, Microbiology Department, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, Sydney, Australia

    8 shared publications
  • David M. Whiley

    UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland

    7 shared publications
  • Athena Limnios

    Neisseria Reference Laboratory, Microbiology Department, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, Sydney, Australia

    6 shared publications
  • Denise Murphy

    Queensland Hlth Sci Serv, Publ Hlth Microbiol, Coopers Plains, Qld, Australia

    5 shared publications
  • Anne Lam

    Prince Wales Hosp, Dept Microbiol, Randwick, NSW, Australia

    4 shared publications
  • Australian Meningococcal Surveillance Programme

    4 shared publications

Latest Publications

  • Characteristics and Population Dynamics of MosaicpenAAllele-ContainingNeisseria gonorrhoeaeIsolates Collected in Sydney, Australia, in 2007-2008

    by John W. Tapsall, Sanghamitra Ray, Athena Limnios

    Eighteen hundredNeisseria gonorrhoeaeisolates collected in Sydney, Australia, in 2007 and 2008 were examined for mosaicpenAalleles that mediated cephalosporin resistance, and the genotypes of the isolates were evaluated. In 2008, there were substantial increases in numbers (from 15 to 85) and proportions (from 1.5 to 10.3%) of mosaic-containing gonococci and major shifts in genotypic patterns, with 10 new genotypes representing 74 of the 85 mosaic-containing isolates and genotypes detected between 2001 and 2005 having disappeared. Enhanced surveillance of gonococcal resistance to cephalosporins is necessary.


    • 1 September 2009
      • Vol. 33  (3) , 259-267

    ANNUAL REPORT OF THE AUSTRALIAN MENINGOCOCCAL SURVEILLANCE PROGRAMME, 2008

    by John Bates, Denise Murphy, Helen Smith, Coopers Plains, Athena Limnios, Sanghamitra Ray, Tiffany Hogan, Anne Lam, John Tapsall, Jo Mercer, et al.

    In 2008, there were 260 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the National Neisseria Network, a nationwide network of reference laboratories. One hundred and forty-nine isolates of Neisseria meningitidis from invasive cases of meningococcal disease were available for which the phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility were determined. An additional 111 cases were confirmed by nonculture based methods. Nationally, 223 (85%) laboratory-confirmed cases where a serogroup was determined were infected with serogroup B and 17 (6.5%) infected with serogroup C meningococci. Nationally, the total number of confirmed cases has remained relatively stable since 2006, but the number of cases in each jurisdiction may vary from year to year. Queensland had the highest number of recorded cases in 2008. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia were again B: 15: P1.7 and B: 4: P1.4. Although serogroup C cases were numerically low, phenotype C: 2a: P1.5 predominated in this group. No evidence of meningococcal capsular ` switching' was detected. About three-quarters of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06-0.5 mg/L). All isolates remained susceptible to ceftriaxone. One isolate had reduced susceptibility to rifampicin and two to ciprofloxacin.


    • 1 September 2009
      • Vol. 33  (3) , 268-274

    ANNUAL REPORT OF THE AUSTRALIAN GONOCOCCAL SURVEILLANCE PROGRAMME, 2008

    by John Bates, Denise Murphy, Vicki Hicks, Coopers Plains, Athena Limnios, Sanghamitra Ray, Tiffany Hogan, Anne Lam, John Tapsall, Geoff Hogg, et al.

    The Australian Gonococcal Surveillance Programme monitors the antibiotic susceptibility of Neisseria gonorrhoeae isolated in all states and territories. In 2008 the in vitro susceptibility of 3,110 isolates of gonococci from public and private sector sources was determined by standardised methods. Different antibiotic susceptibility patterns were again seen in the various jurisdictions and regions. Resistance to the penicillins nationally was at 44% and ranged between 25% in Queensland and 73% in South Australia with the exception of the Northern Territory, where the proportion of drug resistant strains was 4%. Quinolone resistance in gonococci isolates also continued to increase so that nationally 54% of all isolates were ciprofloxacin-resistant, and most of this resistance was at high minimal inhibitory concentrations (MIC) levels. The proportions of quinolone resistant gonococci detected ranged between 80% in South Australia and 31% in Western Australia. All isolates remained sensitive to spectinomycin. Approximately 1.1% of isolates showed some decreased susceptibility to ceftriax-one (MIC 0.06 mg/L or more) and azithromycin resistance was also present in low numbers of gonococci with MICs up to 16 mg/L. A high proportion of gonococci examined in larger urban centres were from male patients and rectal and pharyngeal isolates were common in men. In other centres and in rural Australia the male to female ratio of cases was lower, and most isolates were from the genital tract.


  • Open Access

    Annual report of the Australian Meningococcal Surveillance Programme, 2008

    by Australian Meningococcal Surveillance Programme, John Tapsall

    In 2008, there were 260 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the National Neisseria Network, a nationwide network of reference laboratories. One hundred and forty-nine isolates of Neisseria meningitidis from invasive cases of meningococcal disease were available for which the phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility were determined. An additional 111 cases were confirmed by non-culture based methods. Nationally, 223 (85%) laboratory-confirmed cases where a serogroup was determined were infected with serogroup B and 17 (6.5%) infected with serogroup C meningococci. Nationally, the total number of confirmed cases has remained relatively stable since 2006, but the number of cases in each jurisdiction may vary from year to year. Queensland had the highest number of recorded cases in 2008. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia were again B:15:P1.7 and B:4:P1.4. Although serogroup C cases were numerically low, phenotype C:2a:P1.5 predominated in this group. No evidence of meningococcal capsular 'switching' was detected. About three-quarters of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06–0.5 mg/L). All isolates remained susceptible to ceftriaxone. One isolate had reduced susceptibility to rifampicin and two to ciprofloxacin. Commun Dis Intell 2009;33(3):259–267.


  • Experience with an external quality assurance scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae in India, 2001–2007

    by M. Bala, J. W. Tapsall, A. Limnios, S. Sood, K. Ray

    Antimicrobial resistance (AMR) in Neisseria gonorrhoeae compromises patient treatment and disease control. Epidemiologically based surveillance of AMR in gonococci is needed to optimize standard treatment regimens. Validation of AMR surveillance data depends on external quality assurance schemes (EQAS). AMR surveillance data quality in India during 2001–2007 was assessed by participants testing panels of reference strains and repeated re-challenge with identical controls, accompanied by educative feedback. Overall, correct results were obtained for 944 (82%) of 1030 tests performed for five ‘core’ antibiotics. Aggregated error rates decreased from 33% (123 tests) in 2001 to 4·4% (180 tests) in 2007 with improvements in individual laboratory performance. Cephalosporin test results produced high error rates without improvement. Reference centre and network laboratory collaboration produced marked improvements in test performance through annual EQAS integrating proficiency testing and participant education. More frequent EQAS cycles would assist this process. These experiences may be applicable in similar settings elsewhere.


  • Open Access

    Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods

    by John Tapsall, Phillip Read, Christopher Carmody, Christopher Bourne, Sanghamitra Ray, Athena Limnios, Theo Sloots, David Whiley

    Diagnostic, genotypic and antibiotic-resistance determinants ofNeisseria gonorrhoeaewere analysed by molecular methods to verify the failure of ceftriaxone treatment in two cases of pharyngeal gonorrhoea. Monoplex assays were needed to define competitive inhibition of a positiveChlamydiaPCR in a duplex assay. DifferentpenAchanges were detected in theN. gonorrhoeaeisolated from the two cases. These were associated with raised ceftriaxone MICs of 0.03 and 0.016 mg l−1, which may have contributed to the treatment failures in these cases.


  • Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci

    by J W Tapsall

    To ascertain recommendations for the treatment of gonorrhoea in the WHO Western Pacific Region (WPR) following the emergence of “cephalosporin-resistant” Neisseria gonorrhoeae and to relate these to clinical and laboratory measures directed towards disease and antibiotic resistance control. WHO WPR Gonococcal Antimicrobial Resistance Programme members provided data on the type, dose and source of third-generation cephalosporins recommended for the treatment of gonorrhoea. Ceftriaxone was recommended more widely (11/15 respondents) than cefixime (five centres). No cephalosporins were recommended in three jurisdictions. One other oral (ceftibuten) and injectable (cefodizime) agent was recommended. Uniform (400 mg) doses of cefixime were recommended but ceftriaxone regimens ranged between 125 mg and 1 g, with nine of 11 respondents using a 250 mg dose. Both generic and proprietary preparations were widely used. Third-generation cephalosporins are widely recommended for the treatment of gonorrhoea in the WPR, with injectable ceftriaxone more extensively so than oral cefixime and in an expanded dose range. Few other cephalosporins were recommended. Current knowledge suggests that the trend towards ceftriaxone treatment in higher doses may decrease the impact of the circulation of “cephalosporin-resistant” gonococci in the WPR. These recommendations represent public sector practice only and of themselves are unlikely to contain the further spread of “cephalosporin-resistant” gonococci because of the general clinical use of cephalosporins. Optimisation of strategies for laboratory detection of third-generation cephalosporin resistance can be simplified in the WPR because of the restricted spectrum of cephalosporins recommended. Additional efforts are urgently required for both disease and antibiotic resistance control in gonorrhoea.


  • Open Access

    Annual report of the Australian Meningococcal Surveillance Programme, 2007 – Amended

    by Australian Meningococcal Surveillance Programme, John Tapsall

    In 2007 there were 281 laboratory-confirmed cases of invasive meningococcal disease analysed by the National Neisseria Network, a nationwide network of reference laboratories. The phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility of 154 isolates of Neisseria meningitidis from invasive cases of meningococcal disease were determined and an additional 127 cases were confirmed by non-culture based methods. Nationally, 223 (85%) confirmed cases where a serogroup was determined were infected with serogroup B and 17 (6.5%) with serogroup C meningococci. The total number of confirmed cases was 10 more than the 271 cases identified in 2006. Queensland and New South Wales recorded slight increases in case numbers and Victoria recorded a decline. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia were B:15:P1.7, B:4:P1.4 and C:2a:P1.5. No evidence of meningococcal capsular 'switching' was detected. About three-quarters of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06–0.5 mg/L). All isolates remained susceptible to rifampicin. A single serogroup B isolate had decreased susceptibility to ciprofloxacin (MIC 0.06 mg/L). This was the first local isolate of this type since the original report of this phenomenon in Australia in 2000. Commun Dis Intell 2009;33:1–9 (replacement for Commun Dis Intell 2008;32:299–307).


  • Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins

    by John W Tapsall

    Antibiotic resistance in Neisseria gonorrhoeae poses on-going problems for individual case management and disease control for gonorrhoea. Considerable reliance is now placed on third-generation cephalosporins for the treatment of gonorrhoea following the loss of efficacy of penicillins and quinolones. Current clinical and laboratory perspectives on N. gonorrhoeae with decreased susceptibility to third-generation cephalosporins are provided. Treatment failures following therapy with the oral third-generation cephalosporins cefixime and ceftibuten have been reported, but not with the injectable ceftriaxone. The gonococci involved have raised minimal inhibitory concentrations to these agents, including to ceftriaxone. The presence of multiple chromosomal changes form the basis for this 'resistance', prominent among which is a mosaic penicillin-binding protein 2 found in association with additional known and unknown mutations in other genes. The imprecise nature of laboratory criteria for detecting these gonococci means that the distribution and prevalence of these strains is also uncertain. Concerns regarding the appearance of gonococci associated with treatment failure with oral cephalosporins are increasing. The origins, causes and patterns of spread of these clinically resistant gonococci are reminiscent of the earlier experiences with quinolone-resistant gonococci. Preventive measures require simultaneous implementation of disease-control principles, coupled with those for antimicrobial resistance.


    • 1 June 2008
      • Vol. 32  (2) , 227-231

    ANNUAL REPORT OF THE AUSTRALIAN GONOCOCCAL SURVEILLANCE PROGRAMME, 2007

    by John Bates, Denise Murphy, Vicki Hicks, Athena Limnios, Sanghamitra Ray, Tiffany Shultz, Anne Lam, John Tapsall, Julia Griffith, Mark Bek, et al.

    The Australian Gonococcal Surveillance Programme (AGSP) monitors the antibiotic susceptibility of Neisseria gonorrhoeae isolated in all states and territories. In 2007 the in vitro susceptibility of 3,042 isolates of gonococci from public and private sector sources was determined by standardised methods. The proportion of gonococci resistant to all antibiotics tested nationally was at historically high levels. Different antibiotic susceptibility patterns were again seen in the various jurisdictions and regions. Resistance to the penicillins nationally was at 38% and, with the exception of the Northern Territory, ranged between 24% in Western Australia and 54% in New South Wales. Quinolone resistance in gonococci also continued to increase so that nationally 49% of all isolates were ciprofloxacin-resistant, and most of this resistance was at high MIC levels. Again with the Northern Territory excepted, proportions of quinolone resistant gonococci ranged between 26% in Western Australia and 65% in New South Wales. All isolates remained sensitive to spectinomycin. Approximately 1% of isolates showed some decreased susceptibility to ceftriaxone (MIC 0.06 mg/L or more) and azithromycin resistance was present in low numbers of gonococci. A high proportion of gonococci examined in larger urban centres were from male patients and rectal and pharyngeal isolates were common. In other centres and in rural Australia the male to female ratio of cases was lower, and most isolates were from the genital tract.